|
|
Vaccine Detail
|
MART-1 |
| Vaccine Information |
- Vaccine Name: MART-1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007501
- Type: multipeptide
- Status: Research
- Antigen: gp100, tyrosinase, HLA-A2
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: SD-9427 increased DC numbers in the spleen and peripheral blood and augmented the ability of DCs to efficiently present CTLs and helper peptides. SD-9427 was shown to reproducibly induce initial leukocytosis in all patients. antibodies to G-CSF were detected and peaked at the nadir of the neutrophil count (Pullarkat et al., 2003).
|
| References |
Pullarkat et al., 2003: Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(4); 1301-1312. [PubMed: 12684398].
|
|
